Skip to main content
SpringerLink
Log in

Optimising Acid Inhibition Treatment

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Acid inhibition is safe and useful in several clinical settings. Proton pump inhibitors are more effective than H2-receptor antagonists in virtually all cases. Proton pump inhibitors should be used in: the eradication of Helicobacter pylori; the treatment of non-H. pylori-related peptic ulcer healing; for the prevention and treatment of non-steroidal anti-inflammatory drug-induced upper digestive lesions; for bleeding peptic lesions; and, especially, in the short-term and long-term control of gastro-oesophageal reflux disease. The timing, the dosing and the specific drugs should be adapted to the particular patient, clinical situation and local factors. For instance, in a patient with active bleeding from a duodenal ulcer, intravenous constant infusion should be the preferred treatment. When seeking oral ‘potent’ acid inhibition (refractory gastro-oesophageal reflux disease, and perhaps Barrett’s oesophagus), available data suggest that the pharmacological and clinical profiles of esomeprazole are slightly better.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marzo M, Alonso P, Bonfill X, et al. Guía de Práctica Clínica. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Gastroenterol Hepatol 2002; 25: 85–110

    CAS  Google Scholar 

  2. Mascort JJ, Marzo M, Alonso-Coello P, et al. Guía de Práctica Clínica sobre el manejo del paciente con dispepsia. Gastroenterol Hepatol 2003; 26: 571–613

    Article  PubMed  CAS  Google Scholar 

  3. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345–51

    PubMed  CAS  Google Scholar 

  4. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798–810

    Article  PubMed  CAS  Google Scholar 

  5. Klikenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161–7

    Google Scholar 

  6. Bateman DN, Colin-Jones D, Hartz S, et al. Mortality study of 18000 patients treated with omeprazole. Gut 2003; 52: 942–6

    Article  PubMed  CAS  Google Scholar 

  7. Bamberg P, Caswell CM, Frame MH, et al. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol 1992; 7: 577–85

    Article  PubMed  CAS  Google Scholar 

  8. Eriksson S, Langstrom G, Rikner L, et al. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467–75

    PubMed  CAS  Google Scholar 

  9. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15: 917–26

    Article  PubMed  CAS  Google Scholar 

  10. Gisbert JP, Khorrami S, Calvet X, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists -their efficacy with antibiotics in H. pylori eradication. Aliment Pharmacol Ther 2003; 18: 757–66

    Article  PubMed  CAS  Google Scholar 

  11. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661–5

    PubMed  CAS  Google Scholar 

  12. Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for H. pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149–56

    CAS  Google Scholar 

  13. Forman D, Bazzoli F, Bennett C, et al. Therapies for the eradication of H. pylori (Protocol for the Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; Issue 4. Oxford: Oxford Update Software, 2002.

    Google Scholar 

  14. Gisbert JP, Calvet X, Gomollón F, et al. Conferencia de consenso. Tratamiento erradicador de H. pylori. Reco-mendaciones de la Conferencia Española de Consenso. Med Clin (Barc) 2000; 114: 185–95

    CAS  Google Scholar 

  15. Vergara M, Vallve M, Gisbert JP, et al. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for H. pylori eradication. Aliment Pharmacol Ther 2003; 18: 647–54

    Article  CAS  Google Scholar 

  16. Lanas A, Remacha B, Sáinz S, et al. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol 2000; 95: 513–9

    Article  PubMed  CAS  Google Scholar 

  17. Valenzuela JE, Kogut DG, McCullough AJ, et al. Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study. Am J Gastroenterol 1996; 91: 2516–22

    PubMed  CAS  Google Scholar 

  18. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9

    CAS  Google Scholar 

  19. Lanas A, Piqué JM, Ponce J. Estrategia clínica para el paciente que precisa antiinflamatorios no esteroides: posición de los inhibidores de la COX-2. Gastroenterol Hepatol 2001; 24: 22–36

    PubMed  CAS  Google Scholar 

  20. Lanas A, Rodrigo L, Márquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003; 38: 693–700

    Article  PubMed  CAS  Google Scholar 

  21. Lanas A, Martín-Mola E, Ponce J, et al. Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos. Recomendaciones de la Asociación Española de Gastroenter-ología y de la Sociedad Española de Reumatología. Gastroenterol Hepatol 2003; 26: 485–502

    CAS  Google Scholar 

  22. Barkun A, Bardou M, Marshall JK. Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. Ann Intern Med 2003; 139: 843–57

    PubMed  Google Scholar 

  23. Sung JJY, Chan FL, Lau JYW, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots. A randomized comparison. Ann Intern Med 2003; 139: 237–43

    CAS  Google Scholar 

  24. Khuroo MS, Yatoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: 1054–8

    Article  PubMed  CAS  Google Scholar 

  25. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing rebleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17: 211–6

    Article  PubMed  CAS  Google Scholar 

  26. Gisbert JP, González L, Calvet X, et al. Proton-pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15: 917–26

    Article  PubMed  CAS  Google Scholar 

  27. Zed PJ, Loewen PS, Slavik RS, et al. Meta-analysis of proton-pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001; 35: 1528–34

    Article  PubMed  CAS  Google Scholar 

  28. Dean BB, Gano AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656–64

    Article  PubMed  CAS  Google Scholar 

  29. Leite LP, Johnston BT, Just RJ, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527–31

    PubMed  CAS  Google Scholar 

  30. Vakil N, Fennerty MB. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-esophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559–68

    Article  PubMed  CAS  Google Scholar 

  31. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004; 16: 441–3

    Article  PubMed  CAS  Google Scholar 

  32. Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545–50

    Article  PubMed  Google Scholar 

  33. Omeprazole. Available from URL: http://www.drugs.com/MMX/Omeprazole_Magnesium.html#citec00147746. [Accessed February 5 2001]

  34. Protonix1 (Wyeth-Ayerst) (pantoprazole sodium) Delayed-Release Tablets. Available from URL: http://www.drugs.com/xq/cfm/pageID_0/htm_90406395.htm/type_PDR/bn_PANTOPRAZOLE%20SODIUM/qx/index.htm. [Accessed October 7 2002]

  35. Prevacid® (lansoprazole) Delayed-Release Capsules. Available from URL: http://www.drugs.com/xq/cfm/pageID_0/htm_81001100.htm/type_PDR/bn_LANSOP-RAZOLE/qx/index.htm [Accessed July 1 2002]

  36. Aciphex1 (Eisai) (rabeprazole sodium) Delayed-Release Tablets. Available from URL: http://www.drugs.com//xq/cfm/pageid_0/htm_25750200.htm/tgid_/bn_RABEP-RAZOLE%20SODIUM/type_pdr/qx/index.htm [Accessed January 11 2002]

  37. Nexium® (AstraZeneca LP) (esomeprazole magnesium) delayed release capsules. Available from URL: http://www.drugs.com//xq/cfm/pageid_0/htm_04002180.htm/tgid_/bn_ESOMEPRAZOLE%20MAGNESIUM/type_pdr/qx/index.htm [Accessed January 2 2003]

  38. Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet 2004; 43: 287–90

    Article  PubMed  CAS  Google Scholar 

  39. Andersson T. Single-enantiomer drugs: true therapeutic advances. Clin Pharmacokinet 2004; 43: 279–85

    Article  PubMed  CAS  Google Scholar 

  40. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681–90

    Article  PubMed  CAS  Google Scholar 

  41. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141: 102–12

    PubMed  Google Scholar 

  42. Tinmouth JM, Steele LS, Tomlinson G, et al. Are claims of equivalency in digestive disease trials supported by the evidence? Gastroenterology 2004; 126: 1700–10

    Article  PubMed  Google Scholar 

  43. Navarro MA, Raei N, Torres F, et al. Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration [in Spanish]. Gastroenterol Hepatol 1998; 21: 63–70

    PubMed  CAS  Google Scholar 

  44. Fass R, Thomas S, Traxler B, et al. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patients who failed standard dose PPI versus switching to a different PPI. Gastroenterology 2004; 1264 Suppl 2: A326

    Google Scholar 

  45. McCarthy DM, McLaughlin TP, Griffis DL, et al. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cythochrome P450. Am J Ther 2003; 10: 330–40

    Article  PubMed  Google Scholar 

  46. Labenz J, Petersen KU, Rosch W, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occuring during therapy with omeprazole, lansoprazole, and pantoprazole. Aliment Pharmacol Ther 2003; 17: 1015–9

    Article  PubMed  CAS  Google Scholar 

  47. Hatlebak JG, Katz PO, Camacho-Lobato L, et al. Protonpump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267–72

    Article  Google Scholar 

  48. Mussig S, Witzel L, Luhmann R, et al. Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. Eur J Gastroenterol Hepatol 1997; 9: 599–602

    Article  PubMed  CAS  Google Scholar 

  49. Fraser AG, Sawyerr AM, Hudson M, et al. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996; 10: 523–7

    Article  PubMed  CAS  Google Scholar 

  50. Chiverton SG, Howden CW, Burget DW, et al. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992; 6: 103–11

    Article  PubMed  CAS  Google Scholar 

  51. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235–40

    Article  PubMed  CAS  Google Scholar 

  52. Huang JQ, Hunt RH. Pharmacological and pharmacody-namic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001; 15: 355–70

    Article  PubMed  CAS  Google Scholar 

  53. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004; 19: 1–6

    Article  Google Scholar 

  54. Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux sympton intraesophageal, and intragastric pH in patients with Barrett’s esophagus. Dis Esophagus 2003; 16: 193–8

    Article  PubMed  CAS  Google Scholar 

  55. Spechler SJ. Are we underestimating acid reflux? Gut 2004; 53: 162–3

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Facultad de Medicina, Gastroenterology Service, Clinical University Hospital, Zaragoza, Spain

    Fernando Gomollón (Associate Professor of Medicine)

  2. Digestive Diseases Unit, Sabadell Hospital, ‘Parc Taulí’ University Institute, Autonomous University of Barcelona, Spain

    Xavier Calvet

Authors
  1. Fernando Gomollón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Calvet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Gomollón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomollón, F., Calvet, X. Optimising Acid Inhibition Treatment. Drugs 65 (Suppl 1), 25–33 (2005). https://doi.org/10.2165/00003495-200565001-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565001-00005

Keywords

Search

Navigation